Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Current Applications in Plant-Based Drug Delivery Nano Systems
share announcement

Current Applications in Plant-Based Drug Delivery Nano Systems

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 2893

Special Issue Editors

Dr. Pascaline N. Fru

E-Mail Website
Guest Editor
Department of Surgery, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa
Interests: nano-systems; plant-based; drug delivery systems; cancer treatment and other non-communicable diseases; cell lines; animal models
Dr. Mohammed Balogun

E-Mail Website
Co-Guest Editor
Bio-Polymer Modification and Therapeutics Laboratory, Council for Scientific and Industrial Research (CSIR), Pretoria 0001, South Africa
Interests: nanotechnology; nanomedicine; polymer therapeutics; biopolymers; polymer modification; infectious diseases; biochemistry; organic chemistry; materials science; functional polymers

Special Issue Information

Dear Colleagues,

Given the toxic side effects and the development of chemoresistance with synthetic chemotherapeutics even when included in delivery systems such as nano systems, there is a need to consider less toxic alternatives. The case of polymer drug conjugation is an example even with chemotherapeutics; however, there is no clinically available drug for this purpose either. Naturally derived bioactives could be better alternatives for incorporation into nano-systems but have not been widely explored.

Given this gap in the literature, this Special Issue aims to contribute to the available literature on the current applications of plant-based delivery nano-systems in drug development by taking advantage of the fact that unlike chemotherapeutics, plant-derived compounds are a  less toxic alternative.

In this Special Issue, original research articles and reviews are welcome.

I look forward to receiving your contributions.

Dr. Pascaline N. Fru
Dr. Balogun Mohammed
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nano-systems
  • plant-based drug delivery systems
  • cancer treatment and other non-communicable diseases
  • cell lines
  • animal models

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 2330 KiB  
Article
Valencene, Nootkatone and Their Liposomal Nanoformulations as Potential Inhibitors of NorA, Tet(K), MsrA, and MepA Efflux Pumps in Staphylococcus aureus Strains
by Cícera Datiane de Morais Oliveira-Tintino, Jorge Ederson Gonçalves Santana, Gabriel Gonçalves Alencar, Gustavo Miguel Siqueira, Sheila Alves Gonçalves, Saulo Relison Tintino, Irwin Rose Alencar de Menezes, João Pedro Viana Rodrigues, Vanessa Barbosa Pinheiro Gonçalves, Roberto Nicolete, Jaime Ribeiro-Filho, Teresinha Gonçalves da Silva and Henrique Douglas Melo Coutinho
Pharmaceutics 2023, 15(10), 2400; https://doi.org/10.3390/pharmaceutics15102400 - 28 Sep 2023
Cited by 2 | Viewed by 1016
Abstract
Valencene and nootkatone are aromatic sesquiterpenes with known biological activities, such as antimicrobial, antioxidant, anti-inflammatory, and antitumor. Given the evidence that encapsulation into nanosystems, such as liposomes, could improve the properties of several compounds, the present study aimed to evaluate the activity of [...] Read more.
Valencene and nootkatone are aromatic sesquiterpenes with known biological activities, such as antimicrobial, antioxidant, anti-inflammatory, and antitumor. Given the evidence that encapsulation into nanosystems, such as liposomes, could improve the properties of several compounds, the present study aimed to evaluate the activity of these sesquiterpenes in their isolated state or in liposomal formulations against strains of Staphylococcus aureus carrying efflux pumps. The broth microdilution method evaluated the antibiotic-enhancing activity associated with antibiotics and ethidium bromide (EtBr). The minimum inhibitory concentration was assessed in strains of S. aureus 1199B, IS-58, and RN4220, which carry the efflux proteins NorA, Tet(K), and MsrA. In tests with strain 1199B, valencene reduced the MIC of norfloxacin and EtBr by 50%, while the liposomal formulation of this compound did not show a significant effect. Regarding the strain IS-58, valencene, and its nanoformulation reduced norfloxacin MIC by 60.3% and 50%, respectively. In the non-liposomal form, the sesquiterpene reduced the MIC of EtBr by 90%. Against the RN4220 strain, valencene reduced the MIC of the antibiotic and EtBr by 99% and 93.7%, respectively. Nootkatone and its nanoformulation showed significant activity against the 1199B strain, reducing the EtBr MIC by 21.9%. Against the IS-58 strain, isolated nootkatone reduced the EtBr MIC by 20%. The results indicate that valencene and nootkatone potentiate the action of antibiotics and efflux inhibitors in strains carrying NorA, Tet(K), and MsrA proteins, which suggests that these sesquiterpenes act as efflux pump inhibitors in S. aureus. Therefore, further studies are needed to assess the impact of incorporation into liposomes on the activity of these compounds in vivo. Full article
(This article belongs to the Special Issue Current Applications in Plant-Based Drug Delivery Nano Systems)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 3517 KiB  
Review
A Review of the Potential of Poly-(lactide-co-glycolide) Nanoparticles as a Delivery System for an Active Antimycobacterial Compound, 7-Methyljuglone
by Bianca Diedericks, Anna-Mari Kok, Vusani Mandiwana and Namrita Lall
Pharmaceutics 2024, 16(2), 216; https://doi.org/10.3390/pharmaceutics16020216 - 01 Feb 2024
Viewed by 1286
Abstract
7-Methyljuglone (7-MJ) is a pure compound isolated from the roots of Euclea natalensis A. DC., a shrub indigenous to South Africa. It exhibits significant promise as a potential treatment for the highly communicable disease tuberculosis (TB), owing to its effective antimycobacterial activity against [...] Read more.
7-Methyljuglone (7-MJ) is a pure compound isolated from the roots of Euclea natalensis A. DC., a shrub indigenous to South Africa. It exhibits significant promise as a potential treatment for the highly communicable disease tuberculosis (TB), owing to its effective antimycobacterial activity against Mycobacterium tuberculosis. Despite its potential therapeutic benefits, 7-MJ has demonstrated in vitro cytotoxicity against various cancerous and non-cancerous cell lines, raising concerns about its safety for consumption by TB patients. Therefore, this review focuses on exploring the potential of poly-(lactide-co-glycolic) acid (PLGA) nanoparticles as a delivery system, which has been shown to decrease in vitro cytotoxicity, and 7-MJ as an effective antimycobacterial compound. Full article
(This article belongs to the Special Issue Current Applications in Plant-Based Drug Delivery Nano Systems)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop